Dynavax names new CEO
This article was originally published in Scrip
Executive Summary
Dynavax Technologies, a biopharmaceutical company developing products to prevent and treat infectious and inflammatory diseases, has appointed Eddie Gray chief executive officer and a member of its board of directors, effective 1 May 2013. Before joining Berkeley, California-based Dynavax, Mr Gray served as president of pharmaceuticals Europe at big pharma GlaxoSmithKline. He succeeds Dr Dino Dina as CEO of the Dynavax. Dr Dina will remain a consultant to the firm for the transitional period and plans to continue to serve on the company's board. Additionally, Dr Tyler Martin, president, is departing from Dynavax on 31 May 2013.